A cohort of human immunodeficiency virus (HIV)-infected individuals with documented vaccine-induced hepatitis B surface antibody (HBsAb) seroconversion was evaluated retrospectively to determine factors associated with loss of protective levels of HBsAb. After a median follow-up of 43 months, 111 of the 152 participants (73%) maintained protective levels of HBsAb. HIV RNA suppression at vaccination was associated with persistence of protective levels of HBsAb (odds ratio, 3.83; P < .01). Booster doses were provided for those with loss of protective antibody levels, and hepatitis B virus-specific immune memory, as evaluated with T-cell proliferation assays, was poor despite the observation that boosters successfully reinduced protective levels of HBsAb.
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) are common chronic viral infections that share routes of transmission [1] . HIV-infected individuals have an increased risk of developing chronic HBV infection after exposure, and in those coinfected with HIV and HBV, there is a more rapid progression to end-stage liver disease with increased rates of liver-related morbidity and mortality [2, 3] .
The recombinant hepatitis B surface antigen (HBsAg) vaccine has the potential to prevent HBV infection through the production of protective levels of hepatitis B surface antibody (HBsAb). Among individuals infected with HIV, unlike immunocompetent populations, the HBV vaccine has not been shown to reduce the risk of subsequent HBV infection [4] . Rates of seroconversion are low, and even among those with seroconversion, the protective efficacy of the vaccine is only 50% [4] . Although prior studies from the prehighly active antiretroviral therapy (HAART) era have demonstrated waning of HBsAb levels among persons with HIV, it is unclear if this remains a concern since the widespread introduction of HAART [5] .
This study aims to clarify the natural history of changes in HBsAb levels among HIV-infected individuals after vaccineinduced HBsAb seroconversion and to identify factors associated with loss of protective levels of HBsAb. Anamnestic responses were assessed through HBsAg-specific T-cell proliferation assays and booster response.
METHODS

Design
The study was an observational, retrospective cohort of HIVinfected individuals with documented HBsAb seroconversion in response to the recombinant HBsAg vaccine.
Study Population and Definitions
Study subjects were indentified from 6 academic and community HIV clinics in Toronto, Canada. Inclusion criteria included documented HIV positivity (HIV-1 viremia, or HIV-1 or HIV-2 antibodies by Western blot analysis) and documentation of having received at least 1 dose of recombinant HBsAg vaccine (after the potential participant was known to be HIV positive) with the last documented dose of the initial HBsAg vaccine series between 1 January 1998 and 31 December 2005. The HBsAb seroconversion (defined as HBsAb titer of ≥10 mIU/mL on a serum sample taken after the last dose of recombinant HBsAg vaccine in an individual with prevaccine HBsAb titer of <10 mIU/mL) had to be confirmed. Potential participants were excluded if they had evidence of chronic HBV infection (HBsAg positivity or detectable HBV DNA).
Consent and Ethics
Study subjects currently being seen in the clinic were approached in person for written consent. To minimize survival bias, patients who were lost to follow-up (not seen in clinic in the preceding 12-month period) were contacted by mail to their last known address and were asked to contact the research coordinator by phone or mail for consent. If they did not contact the research coordinator within a 3-month period, then they were enrolled in the study. Those patients who had died were screened and enrolled if they met eligibility criteria. This consent process was approved by the central Research Ethics Board.
Laboratory Measurement
All HBsAb testing was done at 1 of 2 medical laboratories by use of the automated AxSYM system (Abbott). Serostatus and levels of HBsAb were determined from stored serum samples used for routine HIV RNA testing. Titers were expressed in units of milli-international units per milliliter with an HBsAb titer of ≥10 mIU/mL considered to be protective. Loss of protective levels of HBsAb was defined as a decrease to <10 mIU/mL [6] .
Booster Doses
Individuals with loss of protective levels of HBsAb were asked to return to clinic to receive a booster dose of a 40 microgram intramuscular dose of Engerix with HBsAb status determined after at least 1 month.
Statistical Analysis
All analyses were determined a priori. The outcome of interest was the persistence of protective levels of HBsAb during follow-up, and the primary predictor variable was HIV RNA suppression (HIV RNA level of <50 copies/mL; Roche Amplicor test) at the time of the last dose of the initial HBV vaccine series. Other analysis variables included receiving at least 3 doses of the recombinant HBsAg vaccine, CD4 + cell count, comorbid conditions that could impact antibody response (defined as renal failure [creatinine level of >2 times the upper limit of normal or renal replacement therapy], malignancy requiring systemic therapy, alcohol abuse, or diabetes mellitus), hepatitis C virus coinfection, HIV risk group, clinical status, smoking status, race, time elapsed from date of vaccination to outcome determination, age at time of vaccination, and sex. Because of the low probability of HBsAb loss during the first year of follow-up, only participants with follow-up of >12 months in duration were included in the analysis. The association between suppressed HIV RNA, as well as other potential factors, and persistence of protective levels of HBsAb was first compared between individuals with and those without loss of protective immunity by means of univariate methodology. Logistic regression models were used to estimate the effect of virologic suppression on the probability of persistence of protective levels of HBsAb after controlling for other covariates. Variables were included in the model if there was sufficient data completeness and variation within variables as well as our a priori beliefs about their association with persistence of protective level of HBsAb.
T-Cell Proliferation Assays
Ten participants with loss and 10 participants with persistence of protective levels of HBsAb during a minimum of 2 years of followup were randomly selected from the study cohort. Peripheral blood mononuclear cells (PBMCs) were standardized to 100 000 PBMCs per 200 µL of culture medium, and triplicates were made with culture medium alone, 2.5 µg/mL of HBsAb (A. Biologicals), staphylococcal endotoxin B, and tetanus toxoid. Thereafter cultures were incubated at 37°C in 5% CO 2 for 7 days. Proliferation responses were quantified by incorporation of 3H-thymidine (1 microcurie per well; PerkinElmer) added during the last 6 hours of culture. The cells were harvested onto glass fiber filters using a Tomtec cell harvester (Wallac), and incorporated radioactivity level was determined by liquid scintillation counting (Wallac 1205 Betaplate). Results were expressed as mean counts per minute per 10 5 cells and as stimulation index (SI) ratio (counts per minute in stimulated vs unstimulated cultures).
RESULTS
A total of 298 potential participants were approached for consent of whom 250 provided informed consent. Of these, 152 met eligibility criteria and had <12 months of follow-up. The majority of patients were excluded because of either lack of seroconversion or inability to confirm seroconversion. Baseline characteristics of the 152 study participants are presented in Table 1 with univariate analysis according to persistence of protective levels of HBsAb. Only suppressed viral load at the time of vaccination was associated with persistence of HBsAb (P < .01).
Factors included in the final multivariable model included HIV RNA suppression at time of vaccination, CD4 + cell count of >350 cells/μL at time of vaccination, duration of follow-up, receiving at least 3 doses of vaccine, sex, and age ( Of the 41 participants with loss of protective levels of HBsAb during follow-up, 33 participants received a booster dose of 40 μg of Engerix B. Postbooster serology was available for 24 participants (72.7%). All 24 had protective levels of HBsAb induced by boosters of the HBsAg recombinant vaccine, although 3 individuals (12.5%) had low titers of ≤20 mIU/mL. Postbooster titers were not significantly associated with HIV RNA suppression at time of the booster.
T-cell proliferation assays demonstrated that the HBsAb SIs for both the group with persistence and the group with loss of protective levels of HBsAb were poor, with only 20% demonstrating an HBsAg SI of >2 (Supplementary Figure 1) . There was no significant difference among the HBsAg SI values among the 2 groups (P = .21) and no relationship between CD4 + cell count and HBsAg SI (P = .36).
DISCUSSION
Our study demonstrates even in the HAART era, a substantial proportion of HIV-infected individuals lose protective levels of HBsAb after seroconversion in response to the HBV vaccination. We demonstrated that 41 participants (27.0%) followed up for a median of 43 months lost protective levels of HBsAb. This is consistent with limited data available from the HAART era [7] [8] [9] . We did not find any association between CD4 + cell count and persistence of protective levels of HBsAb. The lack of an association in our study may be explained by the relatively immunocompetent population enrolled or may indicate that CD4 + cells are not the predominant cell responsible for persistence of HBsAb in response to HBV vaccination. The latter theory is supported by the lack of a significant association between CD4 + cell count and HBsAb SI when we measured T-cell proliferation responses. Recent data indicating that the generation of HBV-specific memory B cells after recombinant HBsAg vaccination is impaired in HIV-infected individuals further support a T-cell independent mechanism for persistence of HBsAb after vaccine-induced seroconversion [10] . The association between HIV RNA suppression and persistence of protective levels of HBsAb has not been previously demonstrated. Prior studies have demonstrated a strong relationship between HBsAb seroconversion and postvaccination HBsAb titers with ongoing HIV replication [4, 11, 12] . HIV replication at time of vaccination likely leads to loss of protective levels of HBsAb though a blunting of HBsAb response at time of vaccination, leading to lower postvaccination HBsAb titers. HIV viremia likely impacts production of HBsAb through a quantitative and functional decline in activated T cells [13] .
The number of individuals in our cohort who lost protective levels of HBsAb and subsequently received a booster dose of the HBsAg vaccine was small; however, all 24 individuals assessed developed protective levels of HBsAb. The only previous study to evaluate responses to booster doses of vaccine in HIV infection was conducted among children and demonstrated protective HBsAb seropositivity at 1 week after booster of only 45% [14] . This difference might be explained by differences in study design because the former study assessed responses to booster doses regardless of original seroconversion status whereas we assessed only those who lost immunity after known initial seroconversion.
Our study represents the largest cohort of persons with HIV followed up for loss of protective levels of HBsAb in the HAART era and the first to evaluate booster and T-cell proliferation responses. There are several study limitations to be considered when evaluating our findings. First, as the outcome of interest was dependent on time, a preferred analysis plan would have been time to loss of immunity. Viral load samples were not consistently available for the entire duration of follow-up for each individual, making this type of analysis impossible. Second, the retrospective nature of the study limited data availability and completeness. Third, data on hepatitis B core antibodies (HBcAbs) were not available in the vast majority of the study population. Because we did not exclude participants with HBcAb, it is possible that our sample could have included individuals with native immunity and seroreversion prior to receiving the HBV vaccine [15] . Finally, we assumed that an HBsAb titer of 10 mIU/ml was the protective threshold for persons with HIV. Although this value is consistently used in literature evaluating the HBV vaccine in the general population, the true protective threshold for HIV-infected individuals is unknown and unlikely ever to be formalized in a proper randomized controlled trial.
As HIV suppression was the most important variable associated with persistence of protective levels of HBsAb, a potential vaccine strategy to prevent HBsAb loss would be to defer or repeat HBV vaccination after HIV suppression has been achieved. T-cell proliferation assays demonstrated poor response to HBsAg, suggesting that HBV-specific CD4 + T-cells
are not the predominant cell involved in the maintenance of HBsAb. If HBsAb levels fall below protective levels, a booster of the vaccine was shown to return HBsAb levels above the protective threshold.
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